Clinical Experience With the Addition of Pramlintide in Patients With Insulin-Requiring Type 2 Diabetes

Abstract

Pramlintide, a synthetic amylin analog, was approved for type 2 diabetes as an adjunct treatment in patients who have failed to achieve desired glycemic control, despite optimal insulin therapy, with or without concomitant administration of oral antidiabetes agents (1). In clinical trials, pramlintide added to insulin treatment in patients with type 2 diabetes was shown to reduce postprandial glucose levels, improve glycemic control, and promote weight loss (2–8). We reviewed the medical records of our patients with type 2 diabetes who were on pramlintide in addition to insulin treatment to assess the efficacy of mealtime pramlintide on glycemic control and cardiometabolic risk factors in a single endocrine clinical practice setting. We retrospectively studied laboratory and medical parameters of 92 insulin-treated adult patients with type 2 diabetes (54 female, 38 male, aged 24–80 years) recorded at baseline, 12 ± 4 weeks, and 24 ± 4 weeks after initiating pramlintide therapy. Medical and laboratory information were pulled from the main database of the Metabolic Center of Louisiana through a query that extracted information on all patients with type 2 diabetes treated with insulin who were unable to achieve glycemic control and who had completed at least 24 weeks of pramlintide treatment from June 2005 to November 2006. Patients with type 1 diabetes, patients with type …